MRSA Drugs Market 2022: Driving Factors, Business Strategies and Industry Size Forecast to 2027
Market Highlights
Methicillin-resistant Staphylococcus aureus (MRSA) is an
antibiotic resistant strains of the pathogen. MRSA infections are classified as
hospital-acquired (HA-MRSA) or community-acquired (CA-MRSA). MRSA causes
infections such as skin infections, bone and joint infections, bacteremia,
animal infections and others.
According to bulletin of the atomic scientists, about 10
million people in the US (3.6 percent of the population) are
immune-compromised. The World Health Organization estimated that about 36.7
million people had HIV/AIDS worldwide in 2016. Thus, the rising
immune-compromised population is expected to propel the market growth over the
review period. Additionally, growing geriatric population projected to support
the growth of the market since older people are more susceptible to MRSA
infections. World Health Organization estimated that during 2015-2050, the
proportion of the world's population will be nearly double from 12% to 22% and
by 2020, the number of people aged over 60 years likely to outnumber children
younger than 5 years.
Another strong driver is growing concerns of MRSA infections
and increasing government support to curb MRSA. For example, hospital
readmissions reduction program established under Affordable Care Act (ACA)
financially penalizes hospitals if they have higher than expected 30-day
readmission rates for diseases such as pneumonia. The recommendations of the
committee has resulted in hospital readmissions national priority and a direct
financial incentive to reduce readmissions. The financial incentives for reducing
readmissions and the rising cost of non-compliance is expected to benefit the MRSA
drugs market.
High cost of novel drug therapy and low healthcare
expenditure in developing regions projected to hamper the growth of the market
over the review period. Moreover, patent expiry is also expected to lower the
market value due to generic competition. For example, Pfizer’s Zyvox and
Merck’s Cubicin, used for the treatment of MRSA have lost patents in major
markets and their patent for alternative formulations and chemical forms is
threatened by imminent patent expiry dates, which is expected to lower the
market due to competition from generics and greater market fragmentation.
Global MRSA Drugs Market Players
Some of the key players profiled in the report are Merck
KGaA, Olon, Allergan, Baxter, Theravance Biopharma, Pfizer, Mylan N.V,
Novartis, and others.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/2102
Regional Analysis
The Americas accounts for a significant market share owing
to high expenditure on the health care. The fastest uptake of new drugs in the
US drives the MRSA drugs market. Furthermore, concentration of the major
healthcare companies in the developed countries of this region coupled with
large insurance penetration is adding fuel to the market growth. Moreover, the
US expend high amount on its healthcare, which accounts for 16% of total GDP
that also increases the sale in MRSA drugs market.
Europe is the second largest market in the world due to high
income and strong healthcare penetration. The European market growth is led by
countries such as Germany and France. Italy is expected to be the fastest
growing region over the assessment period. The strong pharmaceutical industry
in Germany is a primary driver behind the dominance of this country in Europe.
Southern Europe has a considerable high prevalence of MRSA as compared to
Scandinavian region countries such as Iceland, Norway etc. which is driving the
market faster in these nations.
Asia Pacific region is expected to grow rapidly; China and
India are likely to lead this market due to the fast growing healthcare sector
and large unmet needs over the forecast period. However Asian countries such as
Indonesia, Vietnam, Japan, South Korea, Philippines, and Sri Lanka have higher
prevalence and are expected to contribute highly to the market growth. The
growing penetration of healthcare insurance in the Asia Pacific region is
expected to drive the future MRSA drugs market in the region.
Gulf nations such as Saudi Arabia and the UAE are estimated
to drive the Middle East & African market. Other Middle East nations to
watch out for are Kuwait, Jordan, Egypt and Iran. The African region is
expected to witness a moderate growth owing to poor economic and political
conditions, and poor healthcare development.
Taste the market data and market information presented
through more than 50 market data tables and figures spread over 80 pages of the
project report. Avail the in-depth table of content (TOC) & market synopsis
on “Global MRSA drugs Market” Research Report – Forecast till 2023.
Segmentation
The global MRSA drugs market has been segmented on the basis
of drug class, MRSA types, disease indications, and end user.
Based on the drug class, the market has been segmented as
sulfa drugs, tetracyclines, oxazolidinones, glycopeptide antibiotics, and other.
Based on the MRSA types, the market has been segmented as
hospital-acquired (HA-MRSA) and community-acquired (CA-MRSA).
Based on the disease indications, the market has been
segmented as skin infections, bone and joint infections, bacteremia, animal
infections, and others.
Based on the end user, the market has been segmented as
hospitals & clinics, academic and research, and others.
Access Complete Report @ https://www.marketresearchfuture.com/reports/mrsa-drugs-market-2102
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment